LIXTE Biotechnology shares are trading higher after the company announced the publication of pre-clinical data in the journal EMBO Reports showing that LB-100 increases recognition of colon cancer cells by the immune system.

6/6/24 8:37:39 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $LIXT alert in real time by email

Get the next $LIXT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LIXT

Date	Price Target	Rating	Analyst

More analyst ratings

$LIXT
Press Releases

Fastest customizable press release news feed in the world

LIXTE Receives U.S. Patent Issue Notification for Immune Oncology
Patent Covers Combining LIXTE's LB-100 with Various Innovative Cancer Immunotherapies PASADENA, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) ("LIXTE" or the "Company") today announced it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent application number 16/467,721, titled, "Oxabicycloheptanes for Modulation of Immune Response," for combining the Company's LB-100 compound with various innovative cancer immunotherapies. "The patent award further bolsters LIXTE's existing intellectual property portfolio and underscores the Company's commitment to pioneering research and delivering in
9/4/24 8:30:00 AM ET
$LIXT
Biotechnology: Pharmaceutical Preparations
Health Care
First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company
PASADENA, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) ("LIXTE" or the "Company"), today announced the dosing of the first patient in a new clinical trial in collaboration with the Netherlands Cancer Institute (NKI) and supported by F. Hoffmann-La Roche Ltd. ("Roche") for treatment of unresponsive (MSI Low) metastatic colorectal cancer. As part of the clinical trial (NCT06012734, clinicaltrials.gov), LIXTE is providing its lead compound, LB-100, and Roche is providing atezolizumab (Tecentriq ®, a PDL1 inhibitor) through the imCORE Network, a global academic-industry partnership that aims to accelerate cancer immunotherapy research through inst
8/26/24 8:30:00 AM ET
$LIXT
Biotechnology: Pharmaceutical Preparations
Health Care
LIXTE Biotechnology Provides Update On Recent Activities and Developments
-Collaboration with NKI and Funding Support for New Colorectal Cancer Clinical Trial by Major Pharma Company- -Distinguished Oncologist Jan Schellens Joins LIXTE as Chief Medical Officer- -Preclinical Data Published in Journal EMBO Reports Shows LB-100 as Potentially Enhancing the Benefit of Immunotherapy- -LIXTE to Present at Two Upcoming Investor Conferences- PASADENA, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on the Company's recent activities. "We are
8/19/24 8:30:00 AM ET
$LIXT
Biotechnology: Pharmaceutical Preparations
Health Care

$LIXT
Leadership Updates

Live Leadership Updates

LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer
PASADENA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced the appointment of Jan Schellens, M.D., Ph.D., as Chief Medical Officer (CMO). Dr. Schellens brings to LIXTE more than 25 years of clinical experience as a medical oncologist, pharmacologist and clinical pharmacologist, including more than two decades developing and bringing new drugs to market. He assumes the CMO role at LIXTE effective August 1, 2024, succeeding James S. Miser, M.D., who is leaving the Company after serv
6/3/24 8:30:00 AM ET
$LIXT
Biotechnology: Pharmaceutical Preparations
Health Care
LIXTE Appoints Bas van der Baan as President and Chief Executive Officer
Biotechnology Veteran Bas van der Baan Brings Precision Oncology Expertise; Founder John S. Kovach Named Executive Chairman PASADENA, CA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, announced that Bas van der Baan has been named as President and Chief Executive Officer of the Company, and as Vice Chairman of the Board of Directors, effective as of September 26, 2023. He has been a member of LIXTE'S Board of Directors since June 2022. Mr. van der Baan succeeds John S. Kovach, M.D., 87, who founded the Company in 2005 a
9/26/23 8:30:00 AM ET
$LIXT
Biotechnology: Pharmaceutical Preparations
Health Care
LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORS
PASADENA, CA, June 21, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announced the appointment of Bas van der Baan to its Board of Directors. He will serve as an independent director. Dr. John S. Kovach, Founder and Chief Executive Officer of Lixte, commented, "We are very pleased to welcome Mr. van der Baan to our Board of Directors. Mr. van der Baan has over 20 years of experience in the biotechnology industry with a key focus on oncology and diagnostics. He has extensive knowhow in the journey from clinical development to reimbursement and commercialization
6/21/22 8:30:00 AM ET
$LIXT
Biotechnology: Pharmaceutical Preparations
Health Care

LIXTE Biotechnology shares are trading higher after the company announced the publication of pre-clinical data in the journal EMBO Reports showing that LB-100 increases recognition of colon cancer cells by the immune system.

Chat with this insight

Recent Analyst Ratings for
$LIXT

$LIXT
Press Releases

Fastest customizable press release news feed in the world

LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

LIXTE Biotechnology Provides Update On Recent Activities and Developments

$LIXT
Leadership Updates

Live Leadership Updates

LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORS

$LIXT
SEC Filings

SEC Form 10-Q filed by Lixte Biotechnology Holdings Inc.

Amendment: SEC Form S-1/A filed by Lixte Biotechnology Holdings Inc.

SEC Form DEF 14A filed by Lixte Biotechnology Holdings Inc.

$LIXT
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Bernards Rene bought $24,116 worth of shares (10,000 units at $2.41), increasing direct ownership by 67% to 25,000 units (SEC Form 4) (Amendment)

Van Der Baan Bastiaan Jeroen bought $28,000 worth of shares (10,000 units at $2.80), increasing direct ownership by 1,000% to 11,000 units (SEC Form 4)

Bernards Rene bought $24,116 worth of shares (10,000 units at $2.41), increasing direct ownership by 33% to 20,000 units (SEC Form 4)

$LIXT
Market Insights

Live Market Insights

LIXTE Biotechnology Announces Collaboration With Roche And Netherlands Cancer Institute For Clinical Trial On LB-100's Effectiveness In Enhancing Immune Recognition Of Colon Cancer Cells In MSI Low Metastatic Colon Cancer

LIXTE Biotechnology shares are trading higher after the company announced the publication of pre-clinical data in the journal EMBO Reports showing that LB-100 increases recognition of colon cancer cells by the immune system.

LIXTE Biotechnology Announced Publication Of Data In EMBO Reports Showing LB-100 Increases Recognition Of Colon Cancer Cells By Immune System

$LIXT
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Forman Stephen J.

SEC Form 4 filed by Director Bernards Rene

SEC Form 4 filed by Director Brown Regina

$LIXT
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Lixte Biotechnology Holdings Inc.

SEC Form SC 13G/A filed by Lixte Biotechnology Holdings Inc. (Amendment)

SEC Form SC 13G filed

LIXTE Biotechnology shares are trading higher after the company announced the publication of pre-clinical data in the journal EMBO Reports showing that LB-100 increases recognition of colon cancer cells by the immune system.

Chat with this insight

Recent Analyst Ratings for $LIXT

$LIXT Press Releases

Fastest customizable press release news feed in the world

LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

LIXTE Biotechnology Provides Update On Recent Activities and Developments

$LIXT Leadership Updates

Live Leadership Updates

LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORS

$LIXT SEC Filings

SEC Form 10-Q filed by Lixte Biotechnology Holdings Inc.

Amendment: SEC Form S-1/A filed by Lixte Biotechnology Holdings Inc.

SEC Form DEF 14A filed by Lixte Biotechnology Holdings Inc.

$LIXT Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Bernards Rene bought $24,116 worth of shares (10,000 units at $2.41), increasing direct ownership by 67% to 25,000 units (SEC Form 4) (Amendment)

Van Der Baan Bastiaan Jeroen bought $28,000 worth of shares (10,000 units at $2.80), increasing direct ownership by 1,000% to 11,000 units (SEC Form 4)

Bernards Rene bought $24,116 worth of shares (10,000 units at $2.41), increasing direct ownership by 33% to 20,000 units (SEC Form 4)

$LIXT Market Insights

Live Market Insights

LIXTE Biotechnology Announces Collaboration With Roche And Netherlands Cancer Institute For Clinical Trial On LB-100's Effectiveness In Enhancing Immune Recognition Of Colon Cancer Cells In MSI Low Metastatic Colon Cancer

LIXTE Biotechnology shares are trading higher after the company announced the publication of pre-clinical data in the journal EMBO Reports showing that LB-100 increases recognition of colon cancer cells by the immune system.

LIXTE Biotechnology Announced Publication Of Data In EMBO Reports Showing LB-100 Increases Recognition Of Colon Cancer Cells By Immune System

$LIXT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Forman Stephen J.

SEC Form 4 filed by Director Bernards Rene

SEC Form 4 filed by Director Brown Regina

$LIXT Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Lixte Biotechnology Holdings Inc.

SEC Form SC 13G/A filed by Lixte Biotechnology Holdings Inc. (Amendment)

SEC Form SC 13G filed

Recent Analyst Ratings for
$LIXT

$LIXT
Press Releases

$LIXT
Leadership Updates

$LIXT
SEC Filings

$LIXT
Insider Purchases

$LIXT
Market Insights

$LIXT
Insider Trading

$LIXT
Large Ownership Changes